Estradiol plus olaparib for ER-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This early-stage study tests whether combining estradiol (a form of estrogen) with olaparib (a targeted cancer medicine) can control ER-positive, HER2-negative breast cancer that has spread or come back. It may help by attacking cancer cells in a new way after standard hormone-based treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are post-menopausal and have ER-positive, HER2-negative breast cancer
- Your cancer is metastatic or has returned in a way that can’t be cured with local treatment
- You have already tried at least one hormone (endocrine) treatment for advanced or metastatic breast cancer
- You have not had chemotherapy or another investigational cancer drug within the last 3 weeks
- You have not had radiation therapy within the last 2 weeks
- You do not take strong or moderate medicines that block CYP3A (and you don’t have certain past blood clot or heart/brain conditions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether an estradiol (a form of estrogen) treatment can help people with ER-positive advanced breast cancer. It is mainly for post-menopausal women whose cancer is not curable and has already been treated with endocrine (hormone) therapies.
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
This trial tests if adding a new oral medicine (elacestrant) to a standard PARP inhibitor (olaparib) works better for people with advanced or metastatic HR+/HER2- breast cancer who have a BRCA1 or BRCA2 gene mutation. The goal is to see if the combination can help control the cancer longer.
This study looks at how well the drug Olaparib works in real-world settings for patients with early breast cancer that is HER2-negative. It aims to better understand treatment outcomes.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.